ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

World Lung Cancer Day: Key Insights and Advances in Lung Cancer Trea…

Oncology Data Advisor

S. Kareff, B. Sandy, M. Vojnic

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

ASCO® 2024 Summary: "BEAT Trials and Neoadjuvant Strategies - Advanc…

2024 ASCO® Annual Meeting Insights Hub

M. Marmarelis

ASCO® 2024 Review: Treatment Updates on Unresectable Malignant Pleur…

Nebraska Oncology Society

V. Lam

ASCO® 2024 Insights: "ETOP 13-18 BEAT-meso Trial - Bevacizumab + Che…

2024 ASCO® Annual Meeting Insights Hub

S. Popat

Immunotherapy for Patients With Mesothelioma

MI&T Congressi

J. Aerts

Chemo vs. Chemo + Pembro in 1L Pleural Mesothelioma - 2023 ASCO® Dir…

Total Health

J. Bauman

What’s New in NSCLC & Mesothelioma Immunotherapy

ImmunoTherapy Bridge 2023

A. Morabito

Discovering Research Advances in Mesothelioma

Oncology Data Advisor

S. Kareff, E. Rodriguez

MESOVAX Clinical Trial of Pembro & Dendritic Cell Vaccine in Advance…

Laura Ridolfi

ESMO 2023 Insights: "First Survival Data From the NIPU Trial - Evalu…

Insights from 2023 ESMO Annual Meeting

A. Helland

Updates in Malignant Pleural Mesothelioma

2023 Texas Lung Cancer Conference Coverage

M. Marmarelis

Significant Advances in Mesothelioma

OncoAlert

G. Mountzios

ASCO® 2023 Insights: "Chemo +/- IO for Mesothelioma"

GRACE

J. West, C. Lovly, A. Addeo

ASCO® 2023 Insights: "Pembro in 1L Treatment for Unresectable Advanc…

ecancer

P. Bradbury

ILCC 2022 Mesothelioma: Updates in Systemic Therapy

ILCC 2022 Conference Coverage

P. Baas

WCLC 2022 on Ipilimumab and Nivolumab in Pretreated Patients With Ma…

WCLC 2022 Conference Coverage

M. Jakopovic

ESMO 2021 Updates on 1L Nivo+Ipi for Unresectable Malignant Pleural …

ecancer

S. Peters

WCLC 2022 on the Single Arm Phase II Study PEMMELA: Pembrolizumab + …

WCLC 2022 Conference Coverage

L. Huaqing Douma